Clinical Trials on Esophageal Squamous Cell Carcinoma

Total 12879 results

Zhejiang Cancer Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University

Completed

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients (nabPCESCC)

Esophageal Squamous Cell Carcinoma

China
Fudan University
Zhejiang Cancer Hospital; The First Affiliated Hospital of Anhui Medical University and other collaborators

Unknown

Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0

Esophageal Squamous Cell Carcinoma

China
Samsung Medical Center

Completed

Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma

Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Korea, Republic of
National Cheng-Kung University Hospital

Completed

Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy

Cancer Stem Cell

Taiwan
Beijing Konruns Pharmaceutical Co., Ltd.

Recruiting

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of University of...

Not yet recruiting

AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Sichuan University

Not yet recruiting

A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaborators

Not yet recruiting

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Esophageal Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Henan Provincial People's Hospital

Not yet recruiting

Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Karolinska University Hospital
The Swedish Research Council; University of Leipzig

Recruiting

Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer (NEEDS)

Esophageal Squamous Cell Carcinoma

Canada, Sweden, Norway, Ireland
Ruijin Hospital
The First Affiliated Hospital of Anhui Medical University; The First Affiliated... and other collaborators

Recruiting

Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (PALACE-2)

Esophageal Squamous Cell Carcinoma

China
Baruch Brenner
Bristol-Myers Squibb; Merck Serono International SA

Recruiting

Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.

Esophageal Squamous Cell Carcinoma

Israel
Fujian Medical University Union Hospital

Recruiting

Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
National Taiwan University Hospital

Recruiting

Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC

Chemoradiation | Esophageal Squamous Cell Carcinoma

Taiwan
AstraZeneca

Active, not recruiting

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (KUNLUN)

Esophageal Squamous Cell Carcinoma

Belgium, France, Spain, United States, Thailand, Vietnam, Brazil, Japan, Mexico, Russian Federation, Turkey, China, Taiwan, Canada, Korea, Republic of, Poland
BeiGene

Terminated

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Mian XI

Completed

Identification of Breath Biomarkers in Esophageal Cancer (EC-CRT-005)

Esophageal Squamous Cell Carcinoma

China
Sunshine Lake Pharma Co., Ltd.

Completed

Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

Esophageal Squamous Cell Carcinoma

China
Peking University
Peking University Cancer Hospital & Institute

Suspended

Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Shanghai Cancer Hospital, China

Completed

Precisely Estimation of the Prognostic Value of Lymph Node in ESCC

Esophageal Squamous Cell Carcinoma
Novartis Pharmaceuticals

Completed

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

Taiwan, Spain, Canada, Singapore, Hong Kong, Korea, Republic of, Belgium, United Kingdom, United States
Samsung Medical Center
Ono Pharmaceutical Co. Ltd

Unknown

Neoadjuvant Nivolumab for Operable Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

Korea, Republic of
Samsung Medical Center

Unknown

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

Korea, Republic of
National Cancer Institute (NCI)

Terminated

NCI UNC Project ESCC

Esophageal Squamous Cell Carcinoma

Malawi
Sun Yat-sen University

Completed

Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital

Unknown

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Shandong University

Unknown

Whether it is More Appropriate to Spray Lugol's Solution From Cervical Esophagus to Esophagogastric Junction

Esophageal Squamous Cell Carcinoma
Tiago Biachi

Unknown

Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma (DESC)

Esophageal Squamous Cell Carcinoma

Brazil
Sinocelltech Ltd.
Tianjin Medical University Cancer Institute and Hospital

Unknown

Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Unknown

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Esophageal Squamous Cell Carcinoma

China
Fudan University

Unknown

Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Asan Medical Center

Terminated

Role of Esophagectomy in Complete Responders to CCRT (ESOPRESSO)

Esophageal Squamous Cell Carcinoma

Korea, Republic of
Mianyang Central Hospital

Unknown

S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital
Tongji Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University... and other collaborators

Unknown

Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma

Esophageal Neoplasms

China
Sun Yat-sen University

Recruiting

Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Esophageal Squamous Cell Carcinoma

China
Fudan University

Recruiting

Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

China
Army Medical Center of PLA

Recruiting

A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University

Recruiting

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Efficacy | Toxicity | Esophageal Squamous Cell Carcinoma

China
Guangdong Provincial People's Hospital

Recruiting

Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.

Chemotherapy | Esophageal Squamous Cell Carcinoma | Immunotherapy

China
The First Affiliated Hospital of Soochow University

Recruiting

Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora

Esophageal Squamous Cell Carcinoma | Intestinal Flora

China
Fudan University
Fujian Cancer Hospital; Jiangsu Cancer Institute & Hospital; Ningbo No.2 Hospital and other collaborators

Recruiting

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

Esophageal Squamous Cell Carcinoma | Survival | Chemoradiotherapy

China
Second Affiliated Hospital, School of Medicine,...

Active, not recruiting

Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Esophageal Squamous Cell Carcinoma

China
Fudan University

Recruiting

Local Therapy for Oligometastatic Esophageal Squamous Cell Cancer Patients Treated With PD-1 Inhibitor: a Prospective, Randomized, Phase III Clinical Trial.

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease | Radiotherapy

China

Clinical Trials on Esophageal Squamous Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations